| Gene Symbol | GLUCOCEREBROSIDASE |
| Amino Acids | 497 aa |
| Pathways | Sphingolipid Metabolism, Lipid Metabolism |
| Enzyme deficiency | Reduced GCase activity in PD/DLB |
| Lysosomal dysfunction | GCase loss impairs alpha-synuclein clearance |
| Genetic interaction | GBA1 mutations increase PD risk |
| Therapeutic target | GCase modulators in development |
| Diagnostic utility | Lower GCase helps distinguish PD from essential tremor |
| GBA1 stratification | Identifies PD patients who may benefit from GCase-targeted therapy |
| Progression marker | Lower activity correlates with faster cognitive decline |
| Subtype classification | Helps identify lysosomal dysfunction subtype |
| DLB vs. AD | Lower GCase in DLB than in AD |
| Correlation with pathology | GCase activity inversely correlates with Lewy body burden |
| Prognostic value | Low GCase predicts faster progression |
| Carriers | Heterozygous GBA1 mutation carriers have 5-20x PD risk |
| Associated Diseases | Gaucher disease, Parkinson's disease |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!